Abstract
Ovarian cancer accounts for 3% of cancer deaths among women and is the most lethal gynecological malignancy. The five year survival for all stages collectively is 45.6% and relapsed ovarian cancer is incurable. Platinum resistance is a major prognostic determinant but the molecular pathways involved in resistance mechanism are unknown. Resistance prediction methods are only evolving. The goal of therapy is preservation of performance status and quality of life. Sequential single agent chemotherapy offers the best benefit however no preferred sequence is recommended. Incorporating targeted therapy with conventional chemotherapy presents attractive additional therapeutic options with bevacizumab and olaparib licensed for clinical use. Survival with current management is dismal and enrollment in a clinical trial offers the best scope for platinum resistant ovarian cancer patients.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
